BBOT — Bridgebio Oncology Therapeutics Share Price
0.000.00%
Last trade - 00:00- $978.87m
- $978.21m
- 37
- 27
- 38
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.17 | ||
| Price to Tang. Book | 5.17 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.01% | ||
| Return on Equity | 2.53% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- August 11th, 2025
- Public Since
- February 9th, 2024
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 79,196,710
- Address
- 256 E. Grand Avenue, Suite 104, SOUTH SAN FRANCISCO, 94080
- Web
- https://bbotx.com/
- Phone
- +1 8577020377
- Auditors
Upcoming Events for BBOT
Similar to BBOT
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
FAQ
What is the Bridgebio Oncology Therapeutics share price?
As of Today at 19:42 UTC, shares in Bridgebio Oncology Therapeutics are trading at $12.36. This share price information is delayed by 15 minutes.
How has the Bridgebio Oncology Therapeutics share price performed this year?
Shares in Bridgebio Oncology Therapeutics last closed at $12.36 and the price had moved by +18.56% over the past 365 days. In terms of relative price strength the Bridgebio Oncology Therapeutics share price has outperformed the S&P500 Index by +1.53% over the past year.
What are the analyst and broker recommendations for Bridgebio Oncology Therapeutics?
The overall consensus recommendation for Bridgebio Oncology Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Bridgebio Oncology Therapeutics dividend yield?
Bridgebio Oncology Therapeutics does not currently pay a dividend.
Does Bridgebio Oncology Therapeutics pay a dividend?
Bridgebio Oncology Therapeutics does not currently pay a dividend.
When does Bridgebio Oncology Therapeutics next pay dividends?
Bridgebio Oncology Therapeutics does not currently pay a dividend.
How do I buy Bridgebio Oncology Therapeutics shares?
To buy shares in Bridgebio Oncology Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bridgebio Oncology Therapeutics?
As of the previous close price of $12.36, shares in Bridgebio Oncology Therapeutics had a market capitalisation of $978.87m.
Where are Bridgebio Oncology Therapeutics shares listed?
Here are the trading details for Bridgebio Oncology Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: BBOT
What kind of share is Bridgebio Oncology Therapeutics?
Based on an overall assessment of its quality, value and momentum Bridgebio Oncology Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bridgebio Oncology Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Bridgebio Oncology Therapeutics is $24.20. That is 95.79% above the last closing price of $12.36.
Analysts covering Bridgebio Oncology Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.15 for the next financial year.
Find out moreWhat is the trend in the Bridgebio Oncology Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bridgebio Oncology Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -13.81%.
As of the last closing price of $12.36, shares in Bridgebio Oncology Therapeutics were trading +16.2% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bridgebio Oncology Therapeutics PE Ratio?
The Bridgebio Oncology Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $12.36.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bridgebio Oncology Therapeutics?
We do not have data on Bridgebio Oncology Therapeutics' directors